Possible inj site injury including events of pain, haematoma, haemorrhage & vascular injury; monitor affected patients for signs or symptoms of abdominal haemorrhage. Take extra care when administering in patients w/ low BMI &/or receiving full anticoagulants. Carefully consider & closely monitor men at risk of developing ureteric obstruction or spinal cord compression during the 1st mth of therapy. May reduce bone mineral density. Possible reduced glucose tolerance in males receiving LHRH agonists; may manifest as diabetes or loss of glycaemic control in those w/ pre-existing DM; consider blood glucose monitoring. Prolonged treatment in benign gynaecological conditions >6 mth. May increase uterine cervical resistance. Assess benefit-risk ratio including potential for Torsade de Pointes prior to initiating treatment in patients w/ history of or who have QT prolongation risk factors & in those receiving concomitant medicinal products that may prolong QT interval. Increased risk of MI & sudden cardiac death associated w/ GnRH analogs in men. Not indicated for use in childn.
Zoladex Women w/ known metabolic bone disease. Possible ovarian hyperstimulation syndrome (OHSS) associated in combination w/ gonadotrophin. Carefully monitor stimulation cycle to identify patients at risk of developing OHSS. Assisted reproduction regimens in patients w/ PCOS.
Zoladex LA Only indicated for use in endometriosis, fibroids & breast cancer in premenopausal women. Return of menses after cessation of therapy may be prolonged. May consider multiple treatments in case of disease progression w/o anti-tumour effect of Zoladex.
Sign Out
